» Articles » PMID: 7557078

Turnover of the Gastric H+,K(+)-adenosine Triphosphatase Alpha Subunit and Its Effect on Inhibition of Rat Gastric Acid Secretion

Overview
Specialty Gastroenterology
Date 1995 Oct 1
PMID 7557078
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: The rate of turnover and the effect of inhibition of acid secretion on the turnover of gastric H+,K(+)-adenosine triphosphatase (ATPase) is unknown. The aim of this study was to determine the turnover of the alpha subunit of gastric H+,K(+)-ATPase in rats under control conditions and during inhibition of acid secretion by ranitidine or omeprazole.

Methods: The turnover of the alpha subunit of the ATPase was determined by measuring the loss of incorporated 35S-methionine. This was compared with the rate of recovery of K(+)-stimulated ATPase activity in the omeprazole-treated animals.

Results: The half-life of the alpha subunit was 54 hours. A 1-week treatment with omeprazole had no significant effect, but the half-life increased to 125 hours (P < 0.01) after continuous ranitidine infusion. After omeprazole treatment, K(+)-stimulated ATPase activity recovered with a half-time of 15 hours.

Conclusions: The turnover of the gastric ATPase subunit was independent of omeprazole inhibition but was prolonged by ranitidine. The effect of ranitidine suggests that the resting pump in tubulovesicles may turn over more slowly than the stimulated pump in the secretory canaliculus. The rapid recovery of ATPase activity compared with turnover after omeprazole is caused by both H+,K(+)-ATPase synthesis and loss of covalently bound drug.

Citing Articles

P-CAB PPI in the eradication of : a systematic review and network meta-analysis.

Jiang Y, Zhang R, Fang Y, Zhao R, Fu Y, Ren P Therap Adv Gastroenterol. 2024; 17:17562848241241223.

PMID: 38751605 PMC: 11095192. DOI: 10.1177/17562848241241223.


Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.

Kim H, Yang E, Ban M, Kim Y, Hong S, Jung J Drug Des Devel Ther. 2023; 17:1115-1124.

PMID: 37077412 PMC: 10106809. DOI: 10.2147/DDDT.S392533.


Problems Associated with Deprescribing of Proton Pump Inhibitors.

Helgadottir H, Bjornsson E Int J Mol Sci. 2019; 20(21).

PMID: 31684070 PMC: 6862638. DOI: 10.3390/ijms20215469.


Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials.

Peura D, Le Moigne A, Wassel H, Pollack C BMC Gastroenterol. 2018; 18(1):69.

PMID: 29788903 PMC: 5964662. DOI: 10.1186/s12876-018-0790-2.


Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.

Kinoshita Y, Ishimura N, Ishihara S J Neurogastroenterol Motil. 2018; 24(2):182-196.

PMID: 29605975 PMC: 5885718. DOI: 10.5056/jnm18001.